Reuters logo
8 months ago
BRIEF-GW announces Epidiolex positive Phase 3 data in Dravet syndrome, Lennox-Gastaut syndrome
December 5, 2016 / 12:27 PM / 8 months ago

BRIEF-GW announces Epidiolex positive Phase 3 data in Dravet syndrome, Lennox-Gastaut syndrome

1 Min Read

Dec 5 (Reuters) - GW Pharmaceuticals Plc

* Press release - GW announces new Epidiolex (cbd) positive Phase 3 data in dravet syndrome and lennox-gastaut syndrome

* GW Pharmaceuticals-each pivotal Phase 3 study achieved primary endpoint demonstrating a statistically significant difference between Epidiolex, placebo

* GW Pharmaceuticals Plc - Epidiolex was generally well tolerated

* In both Phase 3 studies, a consistent separation between Epidiolex and placebo across all response rates was seen

* GW Pharmaceuticals - in LGS study, drop seizure responder analysis showed statistically significant separation between Epidiolex & placebo Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below